RUTHERFORD, N.J., May 12, 2015, Cancer Genetics, Inc. (Nasdaq: CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the first quarter ended March 31, 2015.
RUTHERFORD, N.J., May 6, 2015 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics, announced today that it has entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center in Tampa, Florida. The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, […]
RUTHERFORD, NJ – May 5, 2015 – Cancer Genetics, Inc. (NasdaqCM: CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2015 before the market opens on Tuesday, May 12, 2015. The company will hold a live investor conference call and webcast […]
Focus::Myeloid™ will help clinicians and cancer centers improve the management and treatment of more than 275,000 patients in the U.S. currently living with myeloid malignancies Over 100 clinical studies are being conducted by biotechnology and pharmaceutical companies for compounds targeting myeloid cancers that can potentially benefit from CGI’s Focus::Myeloid™ and improvements to enrollment, stratification and […]
Cancer Genetics India (CG India) has launched a Next-Generation Sequencing (NGS) based panel targeting the five most common solid tumors: breast, colorectal, lung, skin, and ovarian cancer for the Indian and broader Asian markets. The NGS-based panel provides a comprehensive genomic assessment of cancer mutations, with dramatically increased sensitivity compared to other testing methodologies, and can be applied to over 370,000 patients annually in India alone.
Cancer Genetics Inc announces NYS licensure for FHACT®, which will allow the company to market the test in New York State
CGI’s full range of oncology focused testing services will be available to an additional 19 million individuals in the US RUTHERFORD, NJ (April 01, 2015): Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, today announced that it has executed an agreement with America’s Choice Provider Network® (ACPN®), an independent national […]
Collaborations with Keck School of Medicine of USC, University of Alabama School of Medicine, and Westchester Medical Center at New York Medical College provide insight into the diagnosis and management of challenging cancers. The collaborations leverage the power of CGI’s unique, proprietary genomic panels, including MatBA® for diffuse large B-cell lymphoma (DLBCL), which is the […]
Fourth Quarter Revenues up 118 Percent Year over Year to $4 million Full-Year 2014 Revenue Increase up 54 Percent over 2013 to $10.2 Million Cancer Genetics to Host Conference Call Today, Thursday March 12th at 8:30 am Eastern Time / 5:30 am Pacific Time RUTHERFORD, N.J., March 12, 2015 – Cancer Genetics, Inc. (Nasdaq: CGIX), […]
Cancer Genetics to Report Fourth Quarter and Fiscal Year 2014 Financial Results on Thursday, March 12
> CGI’s genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC) > Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year RUTHERFORD, NJ, February 24, 2015 (Globe […]
CGI’s unique next generation sequencing (NGS) panel, Focus::CLLTM, will be used to assess genetic aberrations and mutations that are clinically relevant and validated for CLL, the most common form of leukemia in the Western hemisphere. CLL accounts for one-third of all leukemias and the Focus::CLLTM panel helps in determining patient outcome and treatment selection. RUTHERFORD, […]
CEO and President Panna Sharma to participate in the BTIG Second Annual Snowbird Medical Technology, Diagnostics, and Healthcare IT Conference from February 18th to 20th, 2015 in Snowbird, Utah.
Cancer Genetics, Inc. announces appointment of Randy Goodman, Ph.D. as Director of Reimbursement and Clinical Revenue Cycle Management.
Cancer Genetics, Inc. announces that it has begun testing for two clinical trials focused on diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). The total value of the contracts is expected to exceed $2.5 million USD.
Cancer Genetics announces the launch of their ExpandDx™ collaborative testing program. The technical-only testing service provides community hospitals and pathology labs with the most advanced testing technologies available, and facilitates increased collaboration on both atypical and difficult cancer cases.
Cancer Genetics, Inc. announced today that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.
Cancer Genetics, Inc. announces the addition of Venkatadri Bobba to Cancer Genetics India’s Board of Directors.
Cancer Genetics, Inc. announced today that Rob Fannon has joined the company as vice president of operations in the Raleigh/Research Triangle Park (RTP), North Carolina location. Fannon, previously with Roche Molecular’s BioSpecimen Management division, brings more than 10 years of operations, client management, molecular test and panel development, and biorepository management experience to CGI.
Cancer Genetics, Inc. announced today that it has received preliminary approval for a $570,000 tax credit from the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $530,000 in cash in mid-December.